Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTAIN COVID-19: Convalescent Plasma in Hospitalized Patients
NCT04364737Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by NYU Langone Health. Primary endpoint: WHO 11-point Ordinal Scale for Clinical Improvement at 14 days. Started Apr 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04364737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364737.